Sugi Predict

Sugi Predict / Compounds / Hydrochloric Acid

Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1934550

CN(C)[C@@H](CCC(=O)O)C(=O)O.Cl

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP known ✓ O00591 2/20 0.43
▸ GABRD known ✓ O14764 2/20 0.43
▸ GABRA1 known ✓ P14867 2/20 0.43
▸ GABRB1 known ✓ P18505 2/20 0.43
▸ GABRG2 known ✓ P18507 2/20 0.43
▸ GABRB3 known ✓ P28472 2/20 0.43
▸ GABRA5 known ✓ P31644 2/20 0.43
▸ GABRA3 known ✓ P34903 2/20 0.43
▸ GABRA2 known ✓ P47869 2/20 0.43
▸ GABRB2 known ✓ P47870 2/20 0.43
▸ GABRA4 known ✓ P48169 2/20 0.43
▸ GABRE known ✓ P78334 2/20 0.43
▸ GABRA6 known ✓ Q16445 2/20 0.43
▸ GABRG1 known ✓ Q8N1C3 2/20 0.43
▸ GABRG3 known ✓ Q99928 2/20 0.43
▸ GABRQ known ✓ Q9UN88 2/20 0.43
▸ GRIN2D known ✓ O15399 1/20 0.43
▸ GRIN3B known ✓ O60391 1/20 0.43
▸ GRIN1 known ✓ Q05586 1/20 0.43
▸ GRIN2A known ✓ Q12879 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2257624 1.00 CYP1A2 (0.48) CYP1A2TET2KDM4AKDM4CKDM2A
SCHEMBL198528 0.98 CYP1A2 (0.50) CYP1A2TET2KDM4AKDM4CKDM2A
SCHEMBL198527 0.98 CYP1A2 (0.50) CYP1A2TET2KDM4AKDM4CKDM2A
Sulfuric Acid SCHEMBL1521031 0.90 CYP1A2 (0.43) CYP1A2TET2KDM4AKDM4CKDM2A
Sulfuric Acid SCHEMBL1521033 0.90 CYP1A2 (0.43) CYP1A2TET2KDM4AKDM4CKDM2A
SCHEMBL15405381 0.84 LMNA (0.42) CYP1A2FOLH1
SCHEMBL2984816 0.82 CYP1A2 (0.48) CYP1A2TET2KDM4AKDM4CKDM2A
SCHEMBL2984814 0.82 CYP1A2 (0.48) CYP1A2TET2KDM4AKDM4CKDM2A
SCHEMBL14319857 0.82 GABRP (0.43) CYP1A2TET2KDM4AKDM4CKDM2A
SCHEMBL1082587 0.81 FFAR4 (0.44) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 — — US disclosed
CN-112830884-A Salvianic acid A derivative, preparation method and medical application thereof 深圳市高盈医药科技开发有限公司 2021-05-25 — — CN disclosed
US-20180141965-A1 AUTOTAXIN INHIBITORS AND USES THEREOF NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) 2018-05-24 — — US disclosed
US-9174991-B2 Crystalline form of pemetrexed disodium AZAD PHARMACEUTICAL INGREDIENTS AG (CH) 2015-11-03 — — US disclosed
US-20120329819-A1 NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM UNIVERSITY OF ZURICH (CH) 2012-12-27 — — US disclosed
EP-2504341-A1 A NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM Azad Pharmaceutical Ingredients AG (CH) 2012-10-03 — — EP disclosed
US-8193156-B1 Dipeptides incorporating selenoamino acids with enhanced bioavailability—synthesis, pharmaceutical and cosmeceutical applications thereof SAMI LABS LTD 2012-06-05 — — US disclosed
US-8003614-B2 Dipeptides incorporating selenoamino acids with enhanced bioavailability—synthesis, pharmaceutical and cosmeceutical applications thereof SAMI LABS LTD (US) 2011-08-23 — — US disclosed
WO-2011064256-A1 A NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM AZAD PHARMACEUTICAL INGREDIENTS AG (CH) 2011-06-03 — — WO disclosed
US-20080026017-A1 Novel Dipeptides incorporating selenoamino acids with enhanced bioavailability- Synthesis, pharmaceutical and cosmeceutical applications thereof SAMI LABS LIMITED (IN) 2008-01-31 — — US disclosed
EP-0452660-B1 L-glutamic acid derivatives UNIV PRINCETON (US) 1996-05-29 — — EP disclosed
EP-0452660-A2 L-glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1991-10-23 — — EP disclosed
US-5013738-A L-glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1991-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 GABRP 1126/4885GABRD 903/4885GABRA1 990/4885
US-20180141965-A1 AUTOTAXIN INHIBITORS AND USES THEREOF ENPP2, SPINT2, SERPINB1 GABRP 3146/4885GABRD 3986/4885GABRA1 4125/4885
US-20120329819-A1 NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM TYMP, TYMS, MTHFD1 GABRP 3162/4885GABRD 3828/4885GABRA1 4357/4885
US-20080026017-A1 Novel Dipeptides incorporating selenoamino acids with enhanced bioavailability- Synthesis, pharmaceutical and cosmeceutical applications thereof SCLY, CYP2R1, SPR GABRP 1508/4885GABRD 856/4885GABRA1 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.